Greenstone launches rifabutin capsules

PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, announced the introduction of rifabutin capsules to its product line. The capsules are offered in the dosage strength of 150-mg x 100.

The drug is the authorized generic version of Mycobutin and is used for the prevention of disseminated mycobacterium avium complex disease in patients with advanced HIV infection.


Login or Register to post a comment.